BNF:

7.4.2

Status:

Do Not Prescribe (DNP), Grey

Decision Date:

September 2013

Comments

GREY⁶: Another third line choice after a trial of solifenacin and oxybutynin. 

NICE TA290, an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects. (Decision date - August 2020) 

DNP: NICE TA1100 (terminated appraisal) Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (Decision date Nov 2025)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Grey Drug Classifications

• 6: NICE guidance

search again